Interferon-tau inhibits the development of diabetes in NOD mice

References

• Makino S, Tochino Y. The spontaneously nonobese diabetic mouse. Exp Anim 1978; 27: 27–29
   Google Scholar
• Martignal L, Elmansour A, Audrain M, Julian JF, Charbonnel B, Sai P. Pancreatic expression of antigen for islet cell antibodies in nonobese diabetic mice. J Autoimmun 1995; 8: 465–482
   Google Scholar
• Kolika T, Itoh Y, Ishiti T, Ito I, Takabayashi K, Maruyama N, Tomioka H, Yoshida S. Preventive effect of monoclonal anti-L3T4 antibody on development of diabetes in NOD mice. Diabetes 1987; 36: 539–541
   Google Scholar
• Barnard NF, Ertug F, Margolese H. High incidence of thyroiditis and anti-thyroid antibodies in NOD mice. Diabetes 1992; 41: 40–46
   Google Scholar
• Adam C, Thoua TY, Ronco P, Varroust P, Tovey M, Moral-Maroger L. The effect of exogenous interferon: Acceleration of autoimmune and renal diseases in (NZB/W) F1 mice. Clin Exp Immunol 1980; 40: 373–382
   PubMed Web of Science ®Google Scholar
• Stewart TA, Hultgren B, Huang X, Pitts-Meek S, Hully J, MacLachlan NJ. Induction of type 1 diabetes by interferon-α in transgenic mice. Science 1993; 260: 1942–1946
   PubMed Web of Science ®Google Scholar
• Sobel DO, Ahvazi B. α-Interferon inhibits the development of diabetes in NOD mice. Diabetes 1998; 47: 1867–1872
   PubMed Web of Science ®Google Scholar
• Sobel DO, Creswell K, Yoon JW, Holterman D. Alpha interferon administration paradoxically inhibits the development of diabetes in BB rats. Life Sci 1998; 62: 1293–1302
   Google Scholar
• Pontzer CH, Bazer FW, Johnson HM. Antiproliferative activity of a pregnancy hormone, ovine trophoblast protein-1. Cancer Res 1991; 51: 5304–5307
   Google Scholar
• Bazer FW, Spencer TE, Ott L. Placental interferons. Am J Reprod Immunol 1996; 35: 297–308
   Google Scholar
• Li J, Roberts RM. Interferon-tau and interferon-α interact with the same receptors in bovine endometrium: Use of a readily iodinatable form of recombinant interferon-tau for binding studies. J Biol Chem 1994; 269: 13544
   Google Scholar
• Subramanian PS, Khan SA, Pontzer CH, Johnson HM. Differential recognition of the type I receptor by IFN-τ and IFN-alpha is responsible for their differential cytotoxicity. Proc Natl Acad Sci USA 1995; 92: 12270–12274
   Google Scholar
• Radhakrishnan R, Walter LJ, Subramaniam PS, Johnson HM, Walter MR. Crystal structure of ovine interferon-tau at 2.1 A resolution. J Mol Biol 1999; 286: 151–162
   Google Scholar
• Pontzer CH, Ott TL, Bazer FW, Johnson HM. Structure/function studies with interferon tau: Evidence for multiple active sites. J Interferon Res 1994; 14: 133
   Google Scholar
• Stewart DM, Johnson GA, Vyhlidal CA, Burghardt RC, Safe SH, Yu-Lee L-Y, Bazer FW, Spencer TE. Interferon-tau activates multiple signal transducer and activator of transcription proteins and has complex effects on interferon-responsive gene transcription in ovine endometrial epithelial cells. Endocrinol 2001; 142: 98
   Google Scholar
• Soos JM, Subramanian PS, Hobeika AC, Schiffenbauer J, Johnson HM. The IFN pregnancy recognition hormone IFN-τ blocks both development and superantigen reactivation of experimental allergic encephalomyelitis without associated toxicity. J Immunol 1995; 155: 2747
   Google Scholar
• Soos JM, Schiffenbauer J, Johnson HM, Pontzer CH. Interferon tau: A potential treatment for inflammatory central nervous system diseases. Interferon therapy of multiple sclerosis, AT Reder. Marcel Dekker, NY 1996; 479–498
   Google Scholar
• Van Heeke G, Ott TL, Strauss A, Ammaturo D, Bazer FW. High yield expression and secretion of the ovine pregnancy recognition hormone interferon-tau by Pichia pastoris. J Interferon Cytokine Res 1996; 16(2)119–126
   Google Scholar
• Pontzer CH, Johnson HM. Measurement of interferons. Methods Neurosci 1995; 24: 3–9
   Google Scholar
• Brode S, Raine T, Zaccone P, Cooke A. Cyclophosphamide-induced type-1 diabetes in the NOD mouse is associated with a reduction of CD4+CD25+ Foxp3+ regulatory T cells. J Immunol 2006; 177: 6603–6612
   PubMed Web of Science ®Google Scholar
• Venturi GM, Conway RM, Steeber DA, Tedder TF. CD25+CD4+ regulatory T cell migration requires l-selectin expression: l-selectin transcriptional regulation balances constitutive receptor turnover. J Immunol 2007; 178: 291–300
   Google Scholar
• Tarbell KV, Petit L, Zuo X, Toy P, Luo X, Mqadmi A, Yang H, Suthanthiran M, Mojsov S, Steinman RM. Dendritic cell-expanded, islet-specific CD4+CD25+ CD62L+ regulatory T cells restore normoglycemia in diabetic NOD mice. JEM 2007; 204: 191–201
   PubMed Web of Science ®Google Scholar
• Yasunami R, Bach JF. Anti-suppressor effect of cyclophosphamide on the development of spontaneous diabetes in NOD mice. Eur J Immunol 1988; 18: 481–484
   PubMed Web of Science ®Google Scholar
• Mujtaba MG, Soos JM, Johnson HM. CD4 T suppressor cells mediate interferon tau protection against experimental allergic encephalomyelitis. J Neuroimmunol 1997; 75: 35–42
   Google Scholar
• Aune TM, Pierce CW. Activation of suppressor T-cell pathway by interferon. Proc Natl Acad Sci USA 1982; 79: 3606–3812
   Google Scholar
• Serreze DV, Lattar EH. Defective activation of T suppressor cell function in nonobese diabetic mice potential relation to cytokine deficiencies. J Immunol 1988; 140: 3801–3807
   PubMed Web of Science ®Google Scholar
• Lindley S, Dayan CM, Bishop A, Roep BO, Peakman M, Tree TI. Defective suppressor function in CD4+CD25+T-cells from patients with type 1 diabetes. Diabetes 2005; 54: 92–99
   PubMed Web of Science ®Google Scholar
• Thornton AM, Shevach EM. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 1998; 188: 287–296
   PubMed Web of Science ®Google Scholar
• Piccirillo CA, Tritt M, Sgouroudis E, Albanese A, Pyzik M, Hay V. Control of type 1 autoimmune diabetes by naturally occurring CD4+CD25+ regulatory T lymphocytes in neonatal NOD mice. Ann N Y Acad Sci 1998; 105: 72–87
   Google Scholar
• Bennett CL, Christi J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L, Kelly TE, Saulsbury FT, Chance PF, Ochs HD. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001; 27: 20–21
   PubMed Web of Science ®Google Scholar
• Alard P, Manirarora JN, Parnell SA, Hudkins JL, Clark SL, Kosiewicz MM. Deficiency in NOD antigen-presenting cell function may be responsible for suboptimal CD4+CD25+ T-cell-mediated regulation and type 1 diabetes development in NOD mice. Diabetes 2006; 55: 2098–2105
   PubMed Web of Science ®Google Scholar
• Tritt M, Sgouroudis E, d'Hennezel E, Albanese A, Piccirillo CA. Functional waning of naturally occurring CD4+ regulatory T-cells contributes to the onset of autoimmune diabetes. Diabetes 2008; 57: 113–123
   PubMed Web of Science ®Google Scholar
• Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune response. Annu Rev Immunol 2004; 22: 531–562
   PubMed Web of Science ®Google Scholar
• Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245–252
   PubMed Web of Science ®Google Scholar
• Guermonprez P, Valladeau J, Zitvogel L, Théry C, Amigorena S. Antigen Presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 2002; 20: 621–667
   PubMed Web of Science ®Google Scholar
• Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj C. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 2001; 193: 233–238
   PubMed Web of Science ®Google Scholar
• Jonuleit H, Schmitt E, Schuler G, Knop J, Enk AH. Induction of interleukin 10-producing, non-proliferating CD4+T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 2000; 192: 1213–1222
   PubMed Web of Science ®Google Scholar
• Tarbell KV, Yamazaki S, Olson K, Toy P, Steinman RM. CD25+CD4+T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. J Exp Med 2004; 199: 1467–1477
   PubMed Web of Science ®Google Scholar
• Pascale A, Manirarora JN, Parnell SA, Hudkins JL, Clark SL, Kosiewicz MM. Deficiency in NOD antigen-presenting cell function may be responsible for suboptimal CD4+CD25+ T-cell-mediated regulation and type 1 diabetes development in NOD mice. Diabetes 2006; 55: 2098–2105
   Google Scholar
• Liblau RS, Singer SM, McDevitt HO. TH1 and TH2 CD4+ cells in the pathogenesis of organ-specific autoimmune disease. Immunol Today 1995; 16: 34–38
   PubMedGoogle Scholar
• Nichilson LB, Kuchroo VK. Manipulation of the TH1/TH2 balance in autoimmune disease. Curr Opin Immunol 1996; 6: 837–842
   Google Scholar
• Rogez-Kreuz C, Maneglier B, Dereuddre-Bosquet N, Dormont D, Clayette P. Lack of IFN-γ production in response to antigenic stimulation in human IFN-τ-treated lymphocytes. J Interferon Cytokine Res 2005; 25: 444–452
   Google Scholar
• Endharti AT, Rifa IM, 1st, Shi Z, Fukuoka Y, Nakahara Y, Kawamoto Y, Takeda K, Isobe K, Suzuki H. Cutting edge: CD8+CD122+ regulatory T cells produce IL-10 to suppress IFN gamma production and proliferation of CD8+ T cells. J Immunol 2005; 175: 7093–7097
   PubMed Web of Science ®Google Scholar
• Utsugi T, Yoon Y-W, Park B-J, Imamura M, Averill N, Kawazu S, Santamaria P. Major histocompatibility complex Class 1-restricted infiltration and destruction of pancreatic islets by NOD mouse-derived beta-cell cytotoxic CD8+ T-cell clones in vivo. Diabetes 1996; 45: 1121–1131
   PubMed Web of Science ®Google Scholar
• Serreze DV, Leiter EH, Christianson GJ, Greiner D, Roopenian DC. Major histocompatibility complex class I-deficient NOD-B2mnull mice are diabetes and insulitis resistant. Diabetes 1994; 43: 505–509
   PubMed Web of Science ®Google Scholar
• Taki T, Nagata M, Ogawa W, Hatamori N, Hayakawa M, Hari J, Shii K, Baba S, Yokono K. Prevention of cyclophosphamide-induced and spontaneous diabetes in NOD/Shi/Kbe mice by anti-MHC class I Kd monoclonal antibody. Diabetes 1991; 40: 1203–1209
   PubMedGoogle Scholar
• Brod SA, Malone M, Darcan S, Papolla M, Nelson L. Ingested interferon alpha suppresses type 1 diabetes in non-obese diabetic mice. Diabetologia 1998; 41: 1227–1232
   Google Scholar
• Soos JM, Stűve O, Youssef S, Bravo M, Johnson HM, Weiner HL, Zamvil SS. Cutting edge: Oral type I IFN-τ promotes a Th2 bias and enhances suppression of autoimmune encephalomyelitis by oral glatiramer acetate. J Immunol 2002; 169: 2231–2235
   Google Scholar